BENDAMUSTINE HCl
oncology product with a “low side effects” profileFROM A RELIABLE SOURCE
BENDAMUSTINE HCl (monohydrate & anhydrous CAS 3543-75-7) is used in antitumor chemotherapy based on the alkylation mechanism. Main therapeutic area is in hematology; single dosage or in combination with Rituximab.
THERAPEUTIC INDICATION: ONCOLOGY
For the treatment of chronic lymphocytic leukemia and lymphomas.
MARKET INFORMATION
Originator: MUNDIPHARMA
Originator product: RIBOMUSTIN®
Core patent exclusivities: Patents expired
YOUR ADVANTAGES
- Oncology product with a “low side effects” profile
- Good quality API with reliable supply
This article uses material from Wikipedia, which is released under the Creative Commons Attribution-Share-Alike License 3.0.